OCUL Ocular Therapeutix, Inc. Stock Quote

OCUL [NASD]

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	4.66%	Shs Outstand	75.30M	Perf Week	-6.58%
Market Cap	1.59B	Forward P/E	-	EPS next Y	-0.59	Insider Trans	0.01%	Shs Float	63.18M	Perf Month	-5.74%
Income	-96.00M	PEG	-	EPS next Q	-0.17	Inst Own	55.50%	Short Float	9.23%	Perf Quarter	90.22%
Sales	12.30M	P/S	129.32	EPS this Y	-21.20%	Inst Trans	3.85%	Short Ratio	5.09	Perf Half Y	131.83%
Book/sh	-0.07	P/B	-	EPS next Y	52.50%	ROA	-107.60%	Target Price	25.50	Perf Year	327.08%
Cash/sh	0.89	P/C	22.53	EPS next 5Y	-	ROE	-	52W Range	3.78 - 24.30	Perf YTD	-3.24%
Dividend	-	P/FCF	-	EPS past 5Y	6.60%	ROI	-187.80%	52W High	-17.57%	Beta	2.13
Dividend %	-	Quick Ratio	3.50	Sales past 5Y	40.50%	Gross Margin	81.80%	52W Low	430.60%	ATR	1.28
Employees	161	Current Ratio	3.60	Sales Q/Q	637.50%	Oper. Margin	-	RSI (14)	48.57	Volatility	5.65% 6.20%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	52.60%	Profit Margin	-	Rel Volume	0.64	Prev Close	19.65
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 05 AMC	Payout	-	Avg Volume	1.15M	Price	20.03
Recom	2.00	SMA20	-4.16%	SMA50	6.29%	SMA200	86.34%	Volume	733,444	Change	1.93%

Dec-28-20

Downgrade

H.C. Wainwright

Buy → Neutral

Dec-17-20

Initiated

Berenberg

Buy

$27

Nov-13-20

Reiterated

Raymond James

Strong Buy

$15 → $25

Aug-10-20

Reiterated

H.C. Wainwright

Buy

$10 → $13

Mar-03-20

Upgrade

Raymond James

Outperform → Strong Buy

May-21-19

Reiterated

H.C. Wainwright

Buy

$12 → $9

May-21-19

Downgrade

Raymond James

Strong Buy → Outperform

$11 → $5

May-21-19

Downgrade

Cowen

Outperform → Market Perform

$13 → $3

Dec-03-18

Reiterated

Cantor Fitzgerald

Overweight

$22 → $24

Nov-15-18

Initiated

Raymond James

Strong Buy

$10

Sep-07-18

Initiated

Piper Jaffray

Overweight

Oct-24-17

Initiated

Guggenheim

Buy

$12

Jul-26-17

Initiated

H.C. Wainwright

Buy

$10

Jul-12-17

Reiterated

Cantor Fitzgerald

Overweight

$35 → $21

Jun-23-17

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Feb-10-17

Initiated

Cantor Fitzgerald

Overweight

$35

Nov-15-16

Reiterated

RBC Capital Mkts

Outperform

$30 → $32

Aug-11-16

Initiated

JMP Securities

Mkt Outperform

Feb-17-16

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Oct-23-15

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Jan-20-21 08:00AM	Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum Business Wire
Jan-07-21 08:00AM	Ocular Therapeutix Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development Business Wire +5.72%
Jan-06-21 11:24AM	Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options Zacks
Dec-28-20 08:00AM	Ocular TherapeutixTM Announces Exercise of Underwriters Option to Purchase Additional Shares Business Wire -7.65%
Dec-23-20 02:31PM	Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up Zacks
Dec-22-20 08:45AM	Ocular Therapeutix Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis Business Wire +5.27%
Dec-21-20 05:39AM	Here's What We Learned About The CEO Pay At Ocular Therapeutix, Inc. (NASDAQ:OCUL) Simply Wall St.
Dec-15-20 09:47PM	Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock Business Wire
Dec-14-20 04:13PM	Ocular Therapeutix Announces Proposed Public Offering of Common Stock Business Wire +7.67%
Dec-11-20 10:55PM	Is OCUL A Good Stock To Buy Now? Insider Monkey
Nov-23-20 08:00AM	Ocular Therapeutix to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-11-20 09:00AM	Ocular Therapeutix To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting Business Wire
Nov-09-20 04:01PM	Ocular Therapeutix to Participate at Two Upcoming Investor Conferences Business Wire
06:18AM	Ocular Therapeutix Rises 7% On Stellar Results Backed By Dextenza SmarterAnalyst
Nov-06-20 02:13AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised) Zacks +7.00%
Nov-05-20 05:35PM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Ocular Therapeutix Reports Third Quarter 2020 Financial Results and Business Update Business Wire
02:30PM	Ocular Therapeutix, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 08:00AM	Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts Business Wire +14.33%
Oct-30-20 08:00AM	Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia Business Wire
Oct-29-20 12:35PM	Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
12:24PM	Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way? Simply Wall St.
Oct-23-20 07:00AM	Ocular Therapeutix To Report Third Quarter 2020 Financial Results Business Wire
Oct-22-20 07:32AM	Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue? Zacks
Oct-14-20 06:30AM	Ocular Therapeutix Announces Pricing of Public Offering of Common Stock Business Wire -8.92%
Oct-13-20 05:01PM	Ocular Therapeutix Announces Proposed Public Offering of Common Stock Business Wire +10.19%
Oct-08-20 08:00AM	Ocular Therapeutix Announces Topline Phase 1 Clinical Trial Results of OTX-CSI Business Wire
03:46AM	Ocular Lifted By Strong 3Q Prelim Net Product Sales SmarterAnalyst
Oct-07-20 08:00AM	Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter Business Wire +28.66%
Oct-06-20 08:00AM	Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-29-20 08:00AM	Ocular Therapeutix Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Business Wire
Sep-21-20 01:41PM	Do Institutions Own Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares? Simply Wall St.
Sep-10-20 07:00AM	Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children Business Wire
Sep-08-20 07:00AM	Ocular Therapeutix Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant Business Wire
Sep-04-20 12:52PM	Billionaire Ken Griffin Snaps Up These 3 Strong Buy Stocks TipRanks
07:00AM	Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts Business Wire
Sep-03-20 07:00AM	Ocular Therapeutix to Present at Two Upcoming Investor Conferences Business Wire -6.92%
Aug-07-20 08:45AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:34AM	Ocular Therapeutix: Q2 Earnings Insights Benzinga
07:15AM	Ocular Therapeutix Reports Second Quarter 2020 Financial Results and Business Update Business Wire
Aug-06-20 04:08PM	Earnings Outlook for Ocular Therapeutix Benzinga
08:37AM	Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings? Zacks
Aug-05-20 03:30PM	Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Path To Profitability Simply Wall St.
Jul-31-20 07:00AM	Ocular Therapeutix To Report Second Quarter 2020 Financial Results Business Wire
Jul-29-20 12:33PM	Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-23-20 07:00AM	Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts Business Wire
Jul-17-20 07:30AM	Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS) Business Wire
Jul-15-20 07:00AM	Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts Business Wire +10.86%
Jun-15-20 06:38PM	Edited Transcript of OCUL.OQ earnings conference call or presentation 8-May-20 12:30pm GMT Thomson Reuters StreetEvents +10.81%
04:01PM	Ocular Therapeutix to Hold Virtual 2020 Annual Meeting Of Stockholders Business Wire
08:00AM	Ocular Therapeutix to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Business Wire
Jun-14-20 08:24PM	Should You Avoid Ocular Therapeutix Inc (OCUL)? Insider Monkey
Jun-12-20 06:13AM	Is There An Opportunity With Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 46% Undervaluation? Simply Wall St. +5.08%
Jun-10-20 08:00AM	Ocular Therapeutix to Present at the 2020 Raymond James Human Health Innovation Conference Business Wire
May-29-20 08:00AM	Ocular Therapeutix to Present at the Jefferies Virtual Healthcare Conference Business Wire
May-27-20 09:40AM	Small Drug Industry Prospects Bright Amid Coronavirus Gloom Zacks
May-25-20 10:00AM	7 Perfect 10 Stocks to Buy Now TipRanks
May-22-20 04:19PM	Why Ocular Therapeutix Skyrocketed 19.3% Today Motley Fool +19.14%
May-20-20 07:30AM	Ocular Therapeutix Announces Pricing of Public Offering of Common Stock Business Wire
May-19-20 04:44PM	Ocular Therapeutix Announces Proposed Public Offering of Common Stock Business Wire
May-12-20 07:00AM	Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Business Wire
May-11-20 07:00AM	Ocular Therapeutix To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting Business Wire +9.30%
06:52AM	H.C. Wainwright Sticks to Their Buy Rating for Ocular Therapeutix Investing.com
May-09-20 11:30PM	Ocular Therapeutix (OCUL) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 08:43AM	Ocular Therapeutix: Q1 Earnings Insights Benzinga -10.09%
08:25AM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:00AM	Ocular Therapeutix Reports First Quarter 2020 Financial Results and Business Update Business Wire
May-01-20 12:30PM	Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-28-20 07:00AM	Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis Business Wire
Apr-13-20 08:00AM	Ocular Therapeutix Provides Business Update and Response to COVID-19 Global Pandemic Business Wire +5.54%
Mar-31-20 04:56PM	Edited Transcript of OCUL earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents
Mar-12-20 07:45PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates Zacks -19.81%
04:01PM	Ocular Therapeutix Reports Fourth Quarter and Year End 2019 Financial Results and Business Update Business Wire
02:30PM	Ocular Therapeutix, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-20 08:00AM	Ocular Therapeutix To Report Fourth Quarter and Year-End 2019 Financial Results Business Wire
Mar-03-20 07:30AM	Ocular Therapeutix Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference Business Wire +16.42%
Feb-27-20 12:30PM	Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks -7.46%
Feb-25-20 08:00AM	Ocular Therapeutix to Present at the Cowen and Company 40th Annual Health Care Conference Business Wire
Feb-23-20 07:10AM	3 Monster Growth Stocks Primed for Further Gains TipRanks
Feb-18-20 08:10AM	Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven Simply Wall St.
Feb-07-20 08:00AM	Ocular Therapeutix Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference Business Wire +7.87%
Jan-13-20 01:34PM	Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) Overpaying Its CEO? Simply Wall St.
Dec-23-19 03:58PM	Did Hedge Funds Drop The Ball On Ocular Therapeutix Inc (OCUL) ? Insider Monkey +6.22%
Dec-06-19 02:20PM	Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way? Simply Wall St.
Dec-04-19 05:56PM	Edited Transcript of OCUL earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-26-19 08:00AM	Ocular Therapeutix to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
08:00AM	Ocular Therapeutix to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-14-19 08:00AM	Ocular Therapeutix to Present at the Jefferies 2019 London Healthcare Conference Business Wire
Nov-12-19 08:15AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates Zacks -12.29%
07:00AM	Ocular Therapeutix Reports Third Quarter 2019 Financial Results and Business Update Business Wire
Nov-08-19 04:01PM	Ocular Therapeutix Announces Strategic Update and Operational Restructuring Business Wire
Nov-05-19 08:00AM	Ocular Therapeutix To Report Third Quarter 2019 Financial Results Business Wire
07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-30-19 10:33AM	Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-15-19 11:38AM	Moving Average Crossover Alert: Ocular Therapeutix Zacks +7.84%
Oct-01-19 04:24PM	Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019 Business Wire
11:01AM	These 9 Massachusetts companies rank among the 'happiest' in the country American City Business Journals
Sep-26-19 08:00AM	Ocular Therapeutix to Present at the 2019 Cantor Global Healthcare Conference Business Wire -10.34%
Sep-24-19 08:00AM	Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis Business Wire -6.03%
Aug-29-19 08:00AM	Ocular Therapeutix to Present at the 2019 Wells Fargo Healthcare Conference Business Wire

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PEACOCK BRUCE	Director	Dec 03	Option Exercise	5.09	25,000	127,180	25,000	Dec 07 09:30 PM
SUMMER ROAD LLC	10% Owner	Oct 16	Buy	10.48	437	4,580	5,618,861	Oct 20 04:06 PM
SUMMER ROAD LLC	10% Owner	May 19	Buy	5.50	363,636	1,999,998	5,618,424	May 21 04:15 PM
SUMMER ROAD LLC	10% Owner	Mar 24	Buy	4.87	35,052	170,714	5,254,788	Mar 24 09:42 PM
SUMMER ROAD LLC	10% Owner	Mar 23	Buy	4.66	64,948	302,365	5,219,736	Mar 24 09:42 PM
SUMMER ROAD LLC	10% Owner	Mar 20	Buy	4.52	9,100	41,119	5,154,788	Mar 24 09:42 PM
SUMMER ROAD LLC	10% Owner	Mar 19	Buy	4.63	40,900	189,224	5,145,688	Mar 20 09:34 PM
SUMMER ROAD LLC	10% Owner	Mar 18	Buy	4.62	344,938	1,594,200	5,104,788	Mar 20 09:34 PM
SUMMER ROAD LLC	10% Owner	Mar 17	Buy	4.66	550,000	2,562,890	4,759,850	Mar 17 09:35 PM
SUMMER ROAD LLC	10% Owner	Mar 16	Buy	4.16	194,262	807,217	4,209,850	Mar 17 09:35 PM
SUMMER ROAD LLC	10% Owner	Mar 13	Buy	4.63	210,800	975,983	4,015,588	Mar 17 09:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience